Target underlying disease in parallel with symptomatic RP therapy
Immunosuppression for active CTD
Organ-specific therapy (pulmonary vasodilators for PAH)
Digital ulcer prevention and healing
PDE-5 inhibitors preferred for digital ulcer healing
Bosentan for prevention of new ulcers in SSc
IV iloprost for acute crisis and refractory ulcers
Antiplatelet therapy
Low-dose aspirin during acute ischemic crisis
Routine antiplatelet therapy not established for RP generally
Monitoring and treatment escalation
Primary RP annual reassessment
Evolving autoimmune features (15–20% with ANA/abnormal capillaroscopy develop CTD in 2 years)
Serial nailfold capillaroscopy not routine but informative
Secondary RP surveillance
Echocardiography annually for PAH screening in SSc
HRCT chest in SSc patients at baseline and with symptoms
Pulmonary function tests with DLCO annually in SSc
Patient Discharge Instructions
copy discharge instructions
What is Raynaud's phenomenon?
Raynaud's is a condition where blood vessels in your fingers (and sometimes toes) overreact to cold or stress, causing temporary color changes
Your fingers may turn white (blood flow stops), then blue (low oxygen), then red (blood returns)
Attacks usually last 15–20 minutes and resolve with warming
It is a chronic condition that can be managed with lifestyle changes and medications
Avoid your triggers
Cold exposure is the main trigger
Wear gloves and warm clothing outdoors
Avoid holding cold drinks or frozen foods with bare hands
Use insulated cups and oven mitts when cooking
Emotional stress can trigger attacks
Practice relaxation techniques and stress management
If you have significant anxiety, discuss treatment with your doctor
Medications that worsen Raynaud's
Do not start new medications (including cold/allergy medicines) without telling your doctor
Some common medicines like beta-blockers and nasal decongestants can trigger attacks
Your medications
Nifedipine or amlodipine (if prescribed)
Take as directed every day; do not skip doses
Common side effects: headache, ankle swelling, flushing
These side effects often improve over time
Do not use sildenafil (Viagra) type medications if you use nitrate sprays (serious low blood pressure risk)
Always tell your doctor all medications you take
Lifestyle changes
Stop smoking immediately
Smoking severely worsens blood flow to your fingers
Ask your doctor for help with smoking cessation
Exercise regularly
Improves circulation; avoid exercising in cold environments
Keep your whole body warm
Wearing a hat prevents body heat loss that triggers attacks
When to return to the emergency department
A finger remains white or blue for more than 30 minutes despite warming
This may indicate a more serious problem requiring urgent treatment
A fingertip develops an open sore, blister, or black/dark skin
This indicates tissue damage requiring immediate evaluation
Severe pain in a finger that will not go away
You develop new symptoms: fever, joint swelling, skin tightening, difficulty swallowing, or shortness of breath
These may indicate an underlying condition causing your Raynaud's
Chest pain or difficulty breathing
Follow-up appointments
See your family doctor in 2–4 weeks if a new medication was started
If Raynaud's may be related to an underlying condition, you will be referred to a specialist (rheumatologist)
Annual follow-up recommended to monitor for any new developments
References
Guidelines and key sources
Wigley FM, Flavahan NA — Raynaud's Phenomenon
New England Journal of Medicine, 2016
Comprehensive review of pathophysiology, diagnosis, and management
Primary reference for diagnostic criteria and stepwise treatment
Su KY, Sharma M, Kim HJ, et al — Vasodilators for Primary Raynaud's Phenomenon
Cochrane Database of Systematic Reviews, 2021
Nifedipine reduces attack frequency by approximately 1.7 attacks/week vs placebo
Supports CCBs as first-line pharmacotherapy
Rirash F, Tingey PC, Harding SE, et al — Calcium Channel Blockers for Primary and Secondary Raynaud's Phenomenon
Cochrane Database of Systematic Reviews, 2017
Confirms efficacy of CCBs across primary and secondary RP
Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL — Calcium Channel Blockers for Primary Raynaud's Phenomenon
Cochrane Database of Systematic Reviews, 2016
Nifedipine evidence base; tolerability data
Klein-Weigel P, Sander O, Reinhold S, et al — Raynaud's Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care
Deutsches Arzteblatt International, 2021
Long-term management and monitoring recommendations
Haque A, Hughes M — Raynaud's Phenomenon
Clinical Medicine, 2020
Clinical review including risk stratification and treatment algorithm
Pauling JD, Hughes M, Pope JE — Raynaud's Phenomenon — An Update on Diagnosis, Classification and Management
Clinical Rheumatology, 2019
Updated classification and management framework
Ramahi A, Hughes M, Khanna D — Practical Management of Raynaud's Phenomenon
Current Opinion in Rheumatology, 2022
Practical clinical approach for practicing physicians
Di Donato S, Huang S, Pauling JD, et al — Clinically Relevant Differences Between Primary RP and Secondary to CTD
Seminars in Arthritis and Rheumatism, 2024
Key distinguishing features between primary and secondary RP
Hughes M, Ruaro B, McMahan ZH, et al — Raynaud's Phenomenon and Cardiovascular Risk
Seminars in Arthritis and Rheumatism, 2025
RP associated with increased cardiovascular disease and VTE risk independent of traditional risk factors
Markousis-Mavrogenis G, et al — Raynaud Phenomenon and Microvasculopathy in SSc: Multi-Modality Imaging
Current Opinion in Rheumatology, 2023
Role of MRI and imaging in SSc-associated microvascular disease
Kadian-Dodov D — Cold Hands or Feet: Is It Raynaud's or Not?
Medical Clinics of North America, 2023
Differential diagnosis and diagnostic approach
Pope JE — The Diagnosis and Treatment of Raynaud's Phenomenon: A Practical Approach
Drugs, 2007
Stepwise therapeutic approach and drug selection guidance
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.